SEC Filing Summary: ChromaDex Corporation (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ChromaDex Corporation (not Niagen Bioscience, Inc.) on April 21, 2016. The report addresses a specific corporate event regarding the listing status of the company's common stock.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on a regulatory event rather than a periodic financial report.
Material Changes
- NASDAQ Uplisting Approval: On April 21, 2016, the Company announced that its shares of common stock have been approved for uplisting to The NASDAQ Stock Market LLC.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statement disclaimers. It notes that statements regarding future operating results involve risks and uncertainties that could cause actual results to differ materially from anticipated outcomes. No specific financial guidance or management commentary on future performance is included in this text.
Investor Verification Checklist
- Verify the effective date of the NASDAQ uplisting and any associated trading symbol changes.
- Review the attached press release (Exhibit 99.1) for details on the uplisting criteria met by the Company.
- Confirm the Company's current financial status in the most recent 10-Q or 10-K, as this 8-K contains no financial data.